SV

Street Verdict

Analyst Scorecard

A record of what Nuvama Analysis said publicly, with the source. Not advice.

“Sees over 30% upside in Dr. Reddy's Laboratories (DRL) over the next 12 months, citing attractive valuations and robust growth outlook within the pharmaceutical sector.”

Nuvama Analysis’s track record (trackable calls only): 161 graded calls · 95% CI 35–50%

Dr. Reddy's LaboratoriesBullishCalled 12 May 2025
Verdict:PENDING

How this relative call is judged

A relative call is a comparison, judged on closing prices from the first close after the call to the end of its window (3 months when the quote states no time frame). The spread is the pick's return minus the comparator's return: above zero is a hit for a call that favours the pick, and the reverse for a call that marks it down.

Window still open: no verdict until it ends.

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee Nuvama Analysis’s full track record